SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Summit Therapeutics Inc (SMMT) is not a strong buy at this moment for a beginner investor with a long-term horizon. Despite some positive analyst ratings and potential catalysts, the technical indicators, options data, and financial performance suggest caution. The stock's pre-market price increase and bullish moving averages are promising, but the lack of significant trading signals, weak financials, and potential short-term downside risks make it prudent to hold off on buying.
The stock is showing bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive at 0.31, indicating a bullish trend. However, the RSI is neutral at 45.885, and the stock is trading below the pivot level of 23.78, with key support at 19.929. The stock has an 80% chance of declining in the next day (-1.02%), week (-15.88%), and month (-19.88%), which suggests short-term downside risk.
Analysts from Guggenheim and Stifel have Buy ratings with price targets of $40 and $45, citing potential for Summit's ivonescimab drug and upcoming HARMONi-6 data. The selection of HARMONi-6 data for the ASCO plenary session is seen as a positive indicator of its quality.
Jefferies downgraded the stock to Hold with a $15 price target, citing risks in the HARMONi-6 readout and uncertainty in translating results from China to global markets. H.C. Wainwright also lowered its price target to $30 due to delays in key data releases, introducing near-term uncertainty.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved significantly to -$219.17M (up 258.11% YoY), and EPS increased to -0.29 (up 262.50% YoY). Despite these improvements, the company remains unprofitable, with no gross margin.
Mixed analyst sentiment. Guggenheim and Stifel are optimistic with Buy ratings and high price targets, while Jefferies and H.C. Wainwright express caution due to risks and delays in data releases.
